Related Experiment Video
Updated: Jan 29, 2026
06:38
A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells
Published on: January 22, 2021
6.9K
[Chemotherapy in colon cancer]
Bogdan B Tataryn1, Anna Ye Kryzhanivska2, Volodymyr V Golotyuk2
1Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|February 10, 2019
Summary
This study analyzed chemotherapy regimens for 973 colon cancer patients, finding Mejo effective for Stage II, FOLFOX for Stage III, and FOLFIRI for Stage IV colon cancer, improving overall survival rates.
Area of Science:
- Oncology
- Clinical Research
- Chemotherapy
Background:
- Colon cancer (CC) remains a significant global health challenge.
- Optimizing chemotherapy regimens is crucial for improving patient survival rates.
- Understanding treatment efficacy across different disease stages is essential for personalized medicine.
Purpose of the Study:
- To enhance overall survival rates in colon cancer patients.
- To analyze chemotherapy outcomes at the Precarpathian Clinical Oncology Center.
- To correlate specific chemotherapy regimens with colon cancer stage.
Main Methods:
- Retrospective analysis of 973 colon cancer patients.
- Evaluation of direct and long-term chemotherapy results.
- Classification of patients by TNM staging (Stages II, III, and IV).
- Groupings based on chemotherapy regimens: FOLFOX, FOLFIRI, XELOX, Mejo, or phthorafurum monotherapy.
Main Results:
- Stage IV CC: FOLFIRI (40.7%) and FOLFOX (37.3%) were most common.
- Stage III CC: FOLFOX (42.9%) was prevalent, followed by Mejo (27.6%).
- Stage II CC: Mejo (28.8%) and phthorafurum monotherapy (32.2%) were most frequently used.
Conclusions:
- For Stage II CC, Mejo demonstrated the highest 5-year survival rate.
- For Stage III CC, FOLFOX yielded the best survival outcomes.
- For Stage IV CC, FOLFIRI showed the highest survival rates at 1, 2, and 3 years.
More Related Videos
Related Concept Videos
02:22The Colonization of Land
37.6K
Changes in the environment of the early Earth drove the evolution of organisms. As prokaryotic organisms in the oceans began to photosynthesize, they produced oxygen. Eventually, oxygen saturated the oceans and entered the air, resulting in an increase in atmospheric oxygen concentration, known as the oxygen revolution approximately 2.3 billion years ago. Therefore, organisms that could use oxygen for cellular respiration had an advantage. More than 1.5 years ago, eukaryotic cells and...
37.6K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
782
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
782
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
875
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
875
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
660
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
660
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
618
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
618
02:18Cancer
54.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.2K